Cogent Biosciences Announces Presentation at the 44th Annual J.P. Morgan Healthcare Conference
Rhea-AI Summary
Cogent Biosciences (Nasdaq: COGT) announced that Andrew Robbins, President and CEO, will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on January 13, 2026 at 8:15 a.m. PT / 11:15 a.m. ET.
A live webcast will be available on the company’s Investors & Media page at investors.cogentbio.com, with a replay posted approximately two hours after the event and archived for up to 30 days.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, COGT gained 1.52%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
Peers show mixed moves: CLDX -5.33%, DYN -0.98%, IMCR -2.82% alongside modest gains in AUPH +0.86% and MESO +0.16%, suggesting stock-specific dynamics for COGT rather than a uniform biotech sector move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Dec 30 | NDA submission | Positive | -2.1% | NDA filed for bezuclastinib in Non-Advanced Systemic Mastocytosis after pivotal data. |
| Dec 08 | Clinical results | Positive | +4.0% | Positive APEX Part 2 AdvSM data with strong response and biomarker improvements. |
| Nov 14 | Conference participation | Neutral | -0.9% | Planned Jefferies Global Healthcare Conference appearance with webcast access. |
| Nov 11 | Financing priced | Negative | +3.0% | Pricing of equity and 1.625% convertible senior notes due 2031 for capital raise. |
| Nov 10 | Financing proposed | Negative | +119.0% | Announcement of proposed concurrent common stock and convertible notes offerings. |
Recent major positive clinical and regulatory updates often saw mixed or contrary price moves, while equity/debt offerings and financing-related news sometimes coincided with sharp gains, indicating frequent divergence between headline tone and near-term price reaction.
Over the last few months, Cogent progressed bezuclastinib with positive Phase 3 PEAK data in GIST and a Dec 30, 2025 NDA submission for Non-Advanced Systemic Mastocytosis. Financing has been a key theme, including concurrent equity and 1.625% convertible note offerings in early November 2025, followed by completed transactions documented in multiple 8‑K and 424B5 filings. Conference participation on Nov 19, 2025 provided additional investor visibility. Today’s J.P. Morgan conference presentation continues this pattern of investor-focused communications following substantial clinical and financing milestones.
Market Pulse Summary
This announcement details Cogent’s presentation slot at the J.P. Morgan Healthcare Conference on January 13, 2026, with a webcast archived for 30 days. It follows substantial recent milestones, including an NDA filing for Non-Advanced Systemic Mastocytosis and positive PEAK and APEX trial readouts, as well as sizeable equity and convertible note financings. Investors may focus on how management frames clinical progress, regulatory timelines, and capital deployment during this high-visibility event.
AI-generated analysis. Not financial advice.
WALTHAM, Mass. and BOULDER, Colo., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced that Andrew Robbins, President and Chief Executive Officer, will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, January 13, 2026 at 8:15 a.m. PT/11:15 a.m. ET.
A live webcast will be available on the Investors & Media page of Cogent’s website at investors.cogentbio.com. A replay of the webcast will be available approximately two hours after the completion of the event and will be archived for up to 30 days.
About Cogent Biosciences, Inc.
Cogent Biosciences is a biotechnology company focused on developing precision therapies for genetically defined diseases. The most advanced clinical program, bezuclastinib, is a selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. KIT D816V is responsible for driving systemic mastocytosis, a serious disease caused by unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with strong dependence on oncogenic KIT signaling. The company also has an ongoing Phase 1 study of its novel internally discovered FGFR2/3 inhibitor. In addition, the Cogent Research Team is developing a portfolio of novel targeted therapies to help patients fighting serious, genetically driven diseases targeting mutations in ErbB2, PI3Kα, KRAS and JAK2. Cogent Biosciences is based in Waltham, MA and Boulder, CO. Visit our website for more information at www.cogentbio.com. Follow Cogent Biosciences on social media: X (formerly known as Twitter) and LinkedIn. Information that may be important to investors will be routinely posted on our website and X.
Contact:
Christi Waarich
Senior Director, Investor Relations
christi.waarich@cogentbio.com
617-830-1653
FAQ
When will Cogent Biosciences (COGT) present at the J.P. Morgan Healthcare Conference?
Who is presenting for Cogent Biosciences (COGT) at the January 13, 2026 JPM conference?
How can investors watch the Cogent Biosciences (COGT) presentation at JPM 2026?
Will there be a replay of the Cogent Biosciences (COGT) JPM presentation?
What time is the Cogent presentation in Eastern Time for investors in the U.S.?
Where can I find the Cogent Biosciences (COGT) webcast archive after the JPM presentation?
